Buparlisib in Metastatic Transitional Cell Carcinoma of the Urothelium
Phase II Study of Buparlisib in Metastatic Transitional Cell Carcinoma of the Urothelium
Sponsor: Memorial Sloan Kettering Cancer Center
This PHASE2 trial investigates Metastatic Transitional Cell Carcinoma of the Urothelium and is currently completed. Memorial Sloan Kettering Cancer Center leads this study, which shows 13 recorded versions since 2012 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
13 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE2
-
Sep 2021 — Dec 2022 [monthly]
Completed PHASE2
▶ Show 8 earlier versions
-
Jan 2021 — Sep 2021 [monthly]
Completed PHASE2
-
Oct 2020 — Jan 2021 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
May 2020 — Oct 2020 [monthly]
Active Not Recruiting PHASE2
-
May 2019 — May 2020 [monthly]
Active Not Recruiting PHASE2
-
Jun 2018 — May 2019 [monthly]
Active Not Recruiting PHASE2
-
May 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
-
Feb 2017 — May 2017 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Mar 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Memorial Sloan Kettering Cancer Center
- Novartis
For direct contact, visit the study record on ClinicalTrials.gov .